Clinical significance of ALDH2 rs671 polymorphism in esophageal cancer: evidence from 31 case-control studies

Onco Targets Ther. 2015 Mar 23:8:649-59. doi: 10.2147/OTT.S76526. eCollection 2015.

Abstract

Background: Aldehyde dehydrogenase 2 (ALDH2), a critical enzyme for the detoxification of alcohol, is associated with many types of cancers. To verify the relationship of ALDH2 rs671 G>A polymorphism and esophageal cancer (EC), we performed a meta-analysis of a total of 31 published data including 8,510 patients and 16,197 controls.

Methods: The pooled odds ratio (OR) and the 95% confidence interval (CI) were calculated using a fixed or random-effects model. Heterogeneity (PH ), publication bias, and sensitivity analysis were also determined.

Results: Although a protective effort was found in the rs671 homozygote comparison (AA/GG: OR=0.69; 95% CI=0.48-0.98), the heterozygote comparison was apparently associated with the risk of EC, particularly in the Chinese population (

Ag/gg: OR=1.39; 95% CI=1.03-1.87). Alcohol consumption remarkably increased this risk, especially in the AG genotype. Drinking men with the AG genotype appeared to show a higher risk (

Ag/gg: OR=4.39; 95% CI=1.24-6.55) than drinking women.

Conclusion: The present meta-analysis provided advanced information regarding the association of the ALDH2 A>G polymorphism and EC. Taken together, insights from this study suggested an enhanced effect on the development of EC through a genetic-environmental interaction.

Keywords: EC; SNP; aldehyde dehydrogenase-2; esophageal cancer; meta-analysis; single nucleotide polymorphism.